TABLE 4.
Trend in the prevalence of amino acid substitutions in the QRDR of gyrA and/or parC in 126 selected strains
| Straina | No. of isolates with mutation/total no. of isolates
|
P value | |||
|---|---|---|---|---|---|
| 1998-2006 | 1998-1999 | 2000-2001 | 2005-2006 | ||
| PMQR positive | 12/37 | 0/8 | 3/11 | 9/18 | 0.012 |
| CIP-R | 9/14 | 0/3 | 2/2 | 7/9 | |
| CIP-S | 3/23 | 0/5 | 1/9 | 2/9 | |
| PMQR negative | 46/89 | 12/26 | 18/31 | 16/32 | 0.814 |
| CIP-R | 39/40 | 10/10 | 16/16 | 13/14 | |
| CIP-S | 7/49 | 2/16 | 2/15 | 3/18 | |
| Total | 58/126 | 12/34 | 21/42 | 25/50 | 0.214 |
| CIP-R | 48/54 | 10/13 | 18/18 | 20/23 | |
| CIP-S | 10/72 | 2/21 | 3/24 | 5/27 | |
a
CIP-R, ciprofloxacin resistant; CIP-S, ciprofloxacin susceptible.